We are pleased to release a new forensic report on iRhythm Technologies (Nasdaq:
$IRTC) a medical technology and services company that supplies ambulatory cardiac monitors used to detect arrhythmias and other cardiac abnormalities that can indicate atrial fibrillation. We believe the Company's products are largely commoditized, have limited ability to increase margins and are facing growth headwinds. Opportunities to expand into the asymptomatic market are likely to disappoint as wearable devices from companies like hashtag
@Apple $AAPL offer inexpensive solutions. However, we think the greatest underappreciated risks remain federal investigations into its product safety. Shares trade at an approximate 100% - 200% premium to other medical device and service companies. As a result, we see 40%-70% downside risk potential.
sprucepointcap.com/research/…